If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Some cultures have long celebrated and even worshipped the vulva. During the Uruk period (c. 4000–3100 BC), the ancient Sumerians regarded the vulva as sacred and a vast number of Sumerian poems praising the vulva of Inanna, the goddess of love, sex, and fertility, have survived. In Sumerian religion, the goddess Ninimma is the divine personification of the vulva. Vaginal fluid is always described in Sumerian texts as tasting "sweet" and, in a Sumerian bridal hymn, a young maiden rejoices that her vulva has grown hair. Clay models of vulvas were discovered in the temple of Inanna at Ashur. Some major Hindu traditions such as Shaktism, a goddess-centered tradition, revere the vulva and vagina under the name yoni. The goddess as Devi is worshipped as the supreme deity. The yoni is a representation of the female deity and is found in many temples as a focus for prayer and offerings. It is also represented symbolically as a mudra in spiritual practices, including yoga. Sheela na gigs are figurative carvings of naked women displaying an exaggerated vulva. They are found in ancient and medieval European contexts. They are displayed on many churches, but their origin and significance is debatable. A main line of thinking is that they were used to ward off evil spirits. Another view is that the sheela na gig was a divine assistant in childbirth. Starr Goode explores the image and possible meanings of the Sheela na gig and Baubo images in particular, but writes also about the recurring image worldwide.
A Manual for Action. Amsterdam: Amnesty International. ISBN 0939994917. Purkitt, Helen E.; Burgess, Stephen F. (2005). South Africa's Weapons of Mass Destruction. Bloomington, Indiana: Indiana University Press. ISBN 0253345065. Stapleton, Tim (2014). "Bush tracking and warfare in late twentieth-century east and southern Africa". Historia. 59 (2): 229–251. Truth and Reconciliation Commission (1998). "Truth and Reconciliation Commission of South Africa Report. Volume Two" (PDF). Pretoria: Department of Justice and Constitutional Development. White, Luise (2016). "Animals, prey, and enemies: hunting and killing in an African counter-insurgency". Journal of Contemporary African Studies. 34 (1): 7–21. doi:10.1080/02589001.2016.1182746. S2CID 156065621. White, Luise (2021). Fighting and Writing: The Rhodesian Army at War and Postwar. Durham, North Carolina: Duke University Press. ISBN 9781478021285.
The ancestors of coleoids (including most modern cephalopods) and the ancestors of the modern nautilus, had diverged by the Floian Age of the Early Ordovician Period, over 470 million years ago. The Bactritida, a Devonian–Triassic group of orthocones, are widely held to be paraphyletic without the coleoids and ammonoids, that is, the latter groups arose from within the Bactritida. An increase in the diversity of the coleoids and ammonoids is observed around the start of the Devonian period and corresponds with a profound increase in fish diversity. This could represent the origin of the two derived groups. Unlike most modern cephalopods, most ancient varieties had protective shells. These shells at first were conical but later developed into curved nautiloid shapes seen in modern nautilus species. Competitive pressure from fish is thought to have forced the shelled forms into deeper water, which provided an evolutionary pressure towards shell loss and gave rise to the modern coleoids, a change which led to greater metabolic costs associated with the loss of buoyancy, but which allowed them to recolonize shallow waters. However, some of the straight-shelled nautiloids evolved into belemnites. The loss of the shell may also have resulted from evolutionary pressure to increase maneuverability, resulting in a more fish-like habit. There has been debate on the embryological origin of cephalopod appendages. Until the mid-20th century, the "Arms as Head" hypothesis was widely recognized.
Sources: en.wikipedia.org
DFI Retail Group Holdings Limited (formerly known as Dairy Farm International Holdings Limited) is a Hong Kong–based retail company with legal bases in Bermuda and Singapore. A subsidiary of the Jardine Matheson Group, it is a major East and Southeast Asian retailer involved in the processing and wholesaling of food and health and beauty products. Jardine Strategic, a publicly listed holding company, has an attributable 78 percent stake in the firm. It is listed on the London Stock Exchange, with secondary listings on the Singapore Exchange (SGX) and Bermuda Stock Exchange (BSX). The head office is located at Devon House in Taikoo Place, Quarry Bay, Hong Kong. As of 31 December 2020, the Group, its associates and joint ventures operated over 9,997 outlets; Wellcome/Food World (supermarkets), a controlling stake in Maxim's Catering (foodservice), Cold Storage (supermarkets), Jasons Market Place/Market Place by Jasons/Jasons Food Hall (high end supermarkets), Hero (supermarkets), Mannings/Guardian (health and beauty) stores; it also operates 7-Eleven (convenience stores) throughout the region, and IKEA (home furnishings) stores in Hong Kong, Macau, Indonesia and Taiwan. The group and its associates and joint ventures employed more than 220,000 people and had total annual sales in excess of US$28.2 billion.
=== Reproduction === It has been postulated that MCH has a modulatory role with the release of Luteinizing Hormone (LH) either by directly acting on the pituitary gland or indirectly by affecting Gonadotropin-releasing hormone (GNRH) in the hypothalamus. Estrogen seems to be necessary in order for MCH to affect reproduction.
== Side effects == Oclacitinib lacks the side effects that most JAK inhibitors have in humans; instead, side effects are infrequent, mild, and mostly self-limiting. The most common side effects are gastrointestinal problems (vomiting, diarrhea, and appetite loss) and lethargy. The GI problems can sometimes be alleviated by giving oclacitinib with food. New cutaneous or subcutaneous lumps, such as papillomas, can appear, and dogs face an increased susceptibility to infections such as demodicosis. There is a transient decrease in neutrophils, eosinophils, and monocytes, as well as in serum globulin, while cholesterol and lipase levels increase. The decrease in white blood cells lasts only around 14 days. None of the increases or decreases are clinically significant (i.e. none push their corresponding values out of normal ranges). Less common side effects of oclacitinib include bloody diarrhea; pneumonia; infections of the skin, ear, and/or urinary tract; and histiocytomas (benign tumors). Increases in appetite, aggression, and thirst have also been reported.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.